Header

UZH-Logo

Maintenance Infos

Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia


Gloeckner, S F; Meyne, F; Wagner, F; Heinemann, U; Krasnianski, A; Meissner, B; Zerr, I (2008). Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. Journal of Alzheimer's Disease : JAD, 14(1):17-25.

Abstract

We carried out a quantitative analysis of transthyretin (TTR), total tau protein and amyloid-beta (Abeta) peptide (1-40 and 1-42) in the lumbar cerebrospinal fluid of 106 patients with different forms of dementia including Alzheimer's disease (AD), Creutzfeldt-Jakob-disease (CJD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD) and normal pressure hydrocephalus (NPH) in comparison to healthy controls. Our study revealed that Abeta_{1-42} levels were decreased in all patients irrespective of dementia type. Tau protein levels were abnormal in all degenerative dementia except of NPH. Tau levels did not allow differential diagnosis of dementia type except for CJD, where we observed extremely high CSF levels. In other dementia types, levels were elevated in a similar range. Transthyretin levels were selectively decreased in AD and NPH, thus revealing the potential of this protein to be used as additional biomarker in the neurochemical differential diagnosis of AD. A significant negative correlation of TTR CSF levels and disease severity in AD was observed.

Abstract

We carried out a quantitative analysis of transthyretin (TTR), total tau protein and amyloid-beta (Abeta) peptide (1-40 and 1-42) in the lumbar cerebrospinal fluid of 106 patients with different forms of dementia including Alzheimer's disease (AD), Creutzfeldt-Jakob-disease (CJD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD) and normal pressure hydrocephalus (NPH) in comparison to healthy controls. Our study revealed that Abeta_{1-42} levels were decreased in all patients irrespective of dementia type. Tau protein levels were abnormal in all degenerative dementia except of NPH. Tau levels did not allow differential diagnosis of dementia type except for CJD, where we observed extremely high CSF levels. In other dementia types, levels were elevated in a similar range. Transthyretin levels were selectively decreased in AD and NPH, thus revealing the potential of this protein to be used as additional biomarker in the neurochemical differential diagnosis of AD. A significant negative correlation of TTR CSF levels and disease severity in AD was observed.

Statistics

Citations

Dimensions.ai Metrics
74 citations in Web of Science®
78 citations in Scopus®
115 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 09 Apr 2009
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Institute for Regenerative Medicine (IREM)
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Life Sciences > General Neuroscience
Social Sciences & Humanities > Clinical Psychology
Health Sciences > Geriatrics and Gerontology
Health Sciences > Psychiatry and Mental Health
Uncontrolled Keywords:Alzheimer's disease, cerebrospinal fluid, Creutzfeldt-Jakob disease, dementia, total tau, transthyretin
Language:English
Date:2008
Deposited On:09 Apr 2009 12:17
Last Modified:29 Jul 2020 18:52
Publisher:IOS Press
ISSN:1387-2877
OA Status:Closed
Publisher DOI:https://doi.org/10.3233/JAD-2008-14102
PubMed ID:18525124

Download

Closed Access: Download allowed only for UZH members